Nivagen Pharmaceuticals Strengthens Its Strategy Through Business Sale
Nivagen Pharmaceuticals, Inc., a key player in the specialty pharmaceuticals field, has recently taken a bold step by selling its MedisourceRx business unit to a prominent health and wellness company. This strategic transaction was guided by Bourne Partners, who acted as their exclusive financial advisor.
Effects of the MedisourceRx Sale
MedisourceRx, which operates as an FDA-registered 503B outsourcing facility, was integral to Nivagen's operations. The revenue from this sale is allocated to support the creation of an innovative 100,000 square foot sterile manufacturing and R&D facility. This facility is designed to boost Nivagen's manufacturing capabilities as the company ventures into the Contract Development Manufacturing Organization (CDMO) sector.
Improving Manufacturing and Supply Chain
By bringing sterile product manufacturing back to the U.S., Nivagen aims to enhance its supply chain, which should lead to lower manufacturing costs and faster product launches.
Nivagen's Vision Moving Forward
Jay Shukla, Nivagen's CEO, shared his thoughts on this sale, saying, "This strategic move enables Nivagen to concentrate on expanding our cutting-edge sterile injectable manufacturing facility. The sale not only frees up resources but also provides us with a clearer focus on our ANDAs and 505(b)(2) pipeline, propelling our growth further."
About Nivagen Pharmaceuticals
Nivagen is committed to the development, manufacture, and marketing of pharmaceutical products, which include both generics and specialty drugs. The company is especially recognized for its sterile injectables, which encompass IV bags, vials, prefilled syringes, and cartridges, along with offering 503B compounding services tailored for the institutional market.
Facility and Global Distribution
Nivagen features a modern sterile manufacturing facility that can handle various dosage forms. Their global distribution network spans over 50 countries, reinforcing their commitment to providing high-quality, affordable pharmaceutical products to patients around the world.
Understanding Bourne Partners
Bourne Partners is a distinguished financial services firm specializing in the healthcare and pharmaceutical sectors. Based in Charlotte, North Carolina, the firm is well-known for its investment banking and advisory services, drawing on more than twenty years of experience in enhancing capital flow in healthcare.
Dedication to Advancing Healthcare
Bourne Partners is focused on promoting the health and well-being of patients globally. Their expertise and dedication foster valuable collaborations within the healthcare community.
Frequently Asked Questions
What company did Nivagen Pharmaceuticals sell?
Nivagen Pharmaceuticals sold its MedisourceRx business unit to Hims & Hers Health, Inc.
What will Nivagen do with the proceeds from the sale?
The proceeds will be used to build a new sterile manufacturing and R&D facility.
Where is the new manufacturing facility located?
The new state-of-the-art facility will be located in Sacramento.
What is Nivagen’s core focus post-sale?
Post-sale, Nivagen will focus on expanding its sterile injectable manufacturing and advancing its ANDAs and 505(b)(2) pipeline.
What services does Nivagen offer?
Nivagen specializes in the development and manufacturing of generics, specialty drugs, and offers 503B compounding services.
